Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CNTA
stocks logo

CNTA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.393
-32.89%
--
--
-0.412
+106.25%
--
--
-0.404
+6.32%
Estimates Revision
The market is revising Upward the revenue expectations for Centessa Pharmaceuticals plc (CNTA) for FY2025, with the revenue forecasts being adjusted by 4.72% over the past three months. During the same period, the stock price has changed by 87.92%.
Revenue Estimates for FY2025
Revise Upward
up Image
+4.72%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.51%
In Past 3 Month
Stock Price
Go Up
up Image
+87.92%
In Past 3 Month
Wall Street analysts forecast CNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTA is 37.10 USD with a low forecast of 27.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast CNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTA is 37.10 USD with a low forecast of 27.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.560
sliders
Low
27.00
Averages
37.10
High
52.00
Current: 29.560
sliders
Low
27.00
Averages
37.10
High
52.00
Stifel
maintain
2025-11-05
Reason
Stifel
Price Target
2025-11-05
maintain
Reason
Stifel expects shares of Alkermes (ALKS) to move higher on the narcolepsy type 1 data reported by Centessa (CNTA). The initial clinical disclosure from Centessa's orexin program does not look superior to Alkermes' ALKS2680, the analyst tells investors in a research note. Stifel says Alkermes shares were pricing in some fear that Centessa could have a much superior profile. The firm believes orexins could be a "significant blockbuster class" with room for many players. It keeps a Buy rating on Alkermes. The stock in morning trading is up 10%, or $2.90, to $33.29.
Stephens
Loganathan
Overweight
initiated
$35
2025-10-28
Reason
Stephens
Loganathan
Price Target
$35
2025-10-28
initiated
Overweight
Reason
Stephens analyst Sudan Loganathan initiated coverage of Centessa with an Overweight rating and $35 price target. The company's lead asset ORX750 has demonstrated "significant" and dose-dependent improvements in mean sleep latency on the Maintenance of Wakefulness Test, the analyst tells investors in a research note. The firm believes the orexin agonist could have therapeutic benefits to narcolepsy and idiopathic hypersomnia patients.
LifeSci Capital
NULL -> Outperform
initiated
$37
2025-09-03
Reason
LifeSci Capital
Price Target
$37
2025-09-03
initiated
NULL -> Outperform
Reason
LifeSci Capital initiated coverage of Centessa with an Outperform rating and $37 price target.
Wells Fargo
Overweight
initiated
$31
2025-09-02
Reason
Wells Fargo
Price Target
$31
2025-09-02
initiated
Overweight
Reason
Wells Fargo initiated coverage of Centessa with an Overweight rating and $31 price target. Near-term OX2R, orexin-2 receptor, agonism data in narcolepsy type-1,2, and idiopathic hypersomnia, or IH, offer meaningful catalysts for Centessa, the analyst tells investors in a research note. The company's NT2/IH data expected this year should have a greater capacity to re-rate shares, the firm added.
Oppenheimer
Oppenheimer
Outperform
initiated
$40
2025-08-29
Reason
Oppenheimer
Oppenheimer
Price Target
$40
2025-08-29
initiated
Outperform
Reason
Oppenheimer resumed coverage of Centessa with an Outperform rating and $40 price target. The firm cites its conviction for lead asset ORX750 to represent best-in-class potential among orexin-2 receptor agonists, with near-term Phase 2a CRYSTAL-1 data in idiopathic hypersomnia and narcolepsy type-1 and -2 expected this year - likely Q4 2025, given ct.gov information. Presentations at World Sleep for other OX2R agonists should inform the competitive bar for ORX750. Oppenheimer believes the market opportunity for ORX750 is substantial.
Truist
NULL -> Buy
initiated
$30
2025-07-21
Reason
Truist
Price Target
$30
2025-07-21
initiated
NULL -> Buy
Reason
Truist initiated coverage of Centessa with a Buy rating and $30 price target. The firm sees "significant upside potential" for ORX750 in Narcolepsy and Idiopathic Hypersomnia, says the analyst, who views orexin-2 receptor agonist's such as ORX750 as "poised to become the new standard-of-care." While acknowledging that ORX750 is slightly behind competitors, the analyst thinks the drug has the potential to differentiate on safety, efficacy and dosing convenience.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Centessa Pharmaceuticals PLC (CNTA.O) is -18.23, compared to its 5-year average forward P/E of -6.07. For a more detailed relative valuation and DCF analysis to assess Centessa Pharmaceuticals PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.07
Current PE
-18.23
Overvalued PE
-2.40
Undervalued PE
-9.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.47
Undervalued EV/EBITDA
-8.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
164.33
Current PS
0.00
Overvalued PS
966.53
Undervalued PS
-637.88
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 595.44% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 325.14% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 595.44% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CNTA News & Events

Events Timeline

(ET)
2025-12-01
08:40:00
B. Riley Raises Centessa Price Target to $42, Maintains Buy Rating
select
2025-11-12 (ET)
2025-11-12
15:23:26
Morgan Stanley considers Centessa's ORX750 to be 'top-tier' following competitor analysis.
select
2025-11-12
12:02:28
Centessa Shares Increase by 14.0%
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-19NASDAQ.COM
5AM Venture Sells Its Viking Stake—Wise Decision or Lost Chance?

  • 5AM Venture Management's Exit: The firm completely liquidated its position in Viking Therapeutics, selling 189,593 shares for an estimated net position change of $5.02 million, reducing its stake from 1.9% to zero as of Q3 2025.

  • Market Performance: As of November 18, 2025, Viking Therapeutics shares were priced at $38.00, down 5.6% year-to-date, underperforming the S&P 500 by 18.7 percentage points.

  • Investment Perspective: The sale is viewed as a rebalancing strategy rather than a lack of confidence in Viking's drug development, emphasizing the long-term nature of investing in clinical-stage biopharmaceuticals.

  • Investor Insights: The article highlights that individual investors in development-stage biotech must be patient and resilient, as stock movements are primarily driven by clinical data rather than trading activity.

[object Object]
Preview
5.0
11-19NASDAQ.COM
5AM Venture Exits MoonLake Following a Challenging Year: Key Highlights to Note

  • 5AM Venture Management's Exit: The fund sold its entire stake in MoonLake Immunotherapeutics, liquidating 282,313 shares for an estimated $13.33 million, which previously represented 5.12% of its assets.

  • Stock Performance: Following the sale, MoonLake's shares were priced at $13.58, reflecting a 74.9% decline over the past year and significantly underperforming the S&P 500.

  • Risk Management Strategy: The decision to exit the investment is seen as a move to reduce risk amid the stock's poor performance, indicating a shift towards more stable investments.

  • Clinical Development Focus: MoonLake's future hinges on the success of its main drug, sonelokimab, with investor sentiment likely to fluctuate based on clinical trial outcomes and milestones.

[object Object]
Preview
4.0
11-13Benzinga
Wells Fargo Keeps Overweight Rating on Centessa Pharmaceuticals and Increases Price Target to $35

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro equips traders with tools and information designed to improve their chances of success in the markets.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Centessa Pharmaceuticals PLC (CNTA) stock price today?

The current price of CNTA is 29.56 USD — it has increased 1.69 % in the last trading day.

arrow icon

What is Centessa Pharmaceuticals PLC (CNTA)'s business?

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

arrow icon

What is the price predicton of CNTA Stock?

Wall Street analysts forecast CNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTA is 37.10 USD with a low forecast of 27.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Centessa Pharmaceuticals PLC (CNTA)'s revenue for the last quarter?

Centessa Pharmaceuticals PLC revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Centessa Pharmaceuticals PLC (CNTA)'s earnings per share (EPS) for the last quarter?

Centessa Pharmaceuticals PLC. EPS for the last quarter amounts to -0.41 USD, increased 10.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Centessa Pharmaceuticals PLC (CNTA)'s fundamentals?

The market is revising Upward the revenue expectations for Centessa Pharmaceuticals plc (CNTA) for FY2025, with the revenue forecasts being adjusted by 4.72% over the past three months. During the same period, the stock price has changed by 87.92%.
arrow icon

How many employees does Centessa Pharmaceuticals PLC (CNTA). have?

Centessa Pharmaceuticals PLC (CNTA) has 77 emplpoyees as of December 05 2025.

arrow icon

What is Centessa Pharmaceuticals PLC (CNTA) market cap?

Today CNTA has the market capitalization of 4.32B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free